Over the next 3 to 5 years, all going well, this company could have a Market Cap (MC) of around 5_6 billion. With 2.5 billion outstanding shares and provided there is no further dilution, the book value could be around $2.00+. Argue as much as you like, this opportunity at this level is a good risk if you can afford it.
To the naysayers, go somewhere else, IMO your opinion is not welcome on this forum. Why? You have nothing to contribute.
So, piss off!
Ann: Strategic Investment from Sichuan Hebang Biotechnology, page-202
Add AEV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $29.74M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.1¢ | $14.12K | 1.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2012302 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 996420 | 4 |
View Market Depth
| Last trade - 14.30pm 15/11/2024 (20 minute delay) ? |
| AEV (ASX) Chart |